×

ERBA Diagnostics, Inc. Exhibited at AACC 2015 in Atlanta, Georgia, U.S.A.

MIAMI LAKES, Fla., Aug. 3, 2015 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it exhibited its full range of products at the world's largest show for Clinical Chemistry – American Association for Clinical Chemistry (AACC), in Atlanta, Georgia, U.S.A., during July 28-30, 2015.

Suresh Vazirani, Executive Chairman of the Board of Directors of ERBA Diagnostics, said, "We have been exhibiting at the AACC over the last several years with four key objectives: (i) showcase our existing products and new products expected to be launched in the short term; (ii) network with industry peers to explore partnerships with the goal of expanding our product portfolio; (iii) network with attending distributors from various countries with the goal of expanding our channel presence; and (iv) engage, and build relationships with, thought leaders in the health care profession in our efforts to continuously improve our products and services."

"We were pleased with the booth traffic at the exhibition and had the opportunity to showcase our products to customers, and distributors from the U.S. and Latin America. We are excited about the U.S. and Latin American markets opportunities. The congress also provided us with ample opportunity to discuss potential partnerships with other IVD companies globally," added Mr. Vazirani.

ERBA Diagnostics is now strongly focused on expanding their presence in the U.S. and Latin American markets through increased sales and marketing teams and an increased distribution network.

About ERBA Diagnostics, Inc.

ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami Lakes, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, clinical chemistry, hematology and diabetes through its six subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), ImmunoVision, Inc. (U.S.), Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.), and Erba Diagnostics Mexico S.A. (Latin America).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of ERBA Diagnostics, Inc., including, without limitation: ERBA Diagnostics may not be able to achieve its four key objectives, including, without limitation, the risks and uncertainties that ERBA Diagnostics' new products may not be commercially launched when anticipated, or at all, that ERBA Diagnostics may not enter into or otherwise achieve partnerships with industry peers and, if any such partnerships are entered into or achieved, then ERBA Diagnostics may not successfully expand its product portfolio, that ERBA Diagnostics may not successfully expand its channel presence, and that ERBA Diagnostics may not engage or build relationships with thought leaders and, if any such engagement or relationships are entered into or built, then ERBA Diagnostics may not successfully continuously improve its products and services; ERBA Diagnostics may not enter into or otherwise achieve partnerships other IVD companies globally; ERBA Diagnostics may not successfully expand its presence in the U.S. and Latin American markets, whether through increased sales and marketing teams, an increased distribution network or otherwise; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in ERBA Diagnostics' filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading "Risk Factors" in such filings.

CONTACT: Company Contact: Mohan Gopalkrishnan Chief Executive Officer Tel: 305 418 2320 x 319

Source:ERBA Diagnostics Inc